Novo Nordisk (NYSE: NVO) has repurchased DKK 8.4bn in shares

Rhea-AI Filing Summary

Novo Nordisk A/S (NVO) reports progress on its ongoing B share repurchase programme conducted under EU Safe Harbour Rules. The current sub-programme, running from 6 May 2026 to 1 February 2027, authorises repurchases of B shares for up to DKK 11,200,000,010.45, as part of an overall 12‑month share repurchase programme of up to DKK 15 billion beginning 4 February 2026.

Between 17 and 21 August 2026, the company repurchased 1,045,000 B shares, bringing the accumulated amount under the 6 May programme to 15,170,000 B shares with a transaction value of DKK 4,590,476,842. Novo Nordisk now holds 43,969,876 B shares as treasury shares, equal to 1.0% of the total share capital of 4,465,000,000 A and B shares. Since 4 February 2026, it has repurchased 29,929,179 B shares at an average price of DKK 280.34, for a total of DKK 8,390,476,831.

Key Figures

Overall share repurchase programme size: DKK 15 billion Sub-programme maximum amount: DKK 11,200,000,010.45 Accumulated repurchases under 6 May 2026 programme: 15,170,000 B shares; DKK 4,590,476,842 +5 more

8 metrics

Overall share repurchase programme size DKK 15 billion Expected B share repurchases during 12‑month period beginning 4 February 2026

Sub-programme maximum amount DKK 11,200,000,010.45 B share repurchases from 6 May 2026 to 1 February 2027

Accumulated repurchases under 6 May 2026 programme 15,170,000 B shares; DKK 4,590,476,842 Total under the programme as of 21 August 2026

Total repurchases since 4 February 2026 29,929,179 B shares; DKK 8,390,476,831 At an average price of DKK 280.34 per B share

Treasury shares 43,969,876 B shares Held as treasury shares, equal to 1.0% of share capital

Total A and B shares 4,465,000,000 shares Total share capital including treasury shares

Employees About 68,800 Employees in 80 countries

Markets Around 170 countries Countries where products are marketed

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, American Depositary Receipts, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"Novo Nordisk owns a total of 43,969,876 B shares ... as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"in accordance with ... 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

American Depositary Receipts financial

"Its ADRs are listed on the New York Stock Exchange (NVO)."

A certificate traded on U.S. markets that represents ownership of shares in a foreign company, letting U.S. investors buy and sell that company as if it were listed domestically. Think of it as a local voucher for a foreign product: it makes price quotes in dollars, trades on familiar exchanges, and brings differences in liquidity, fees and legal protections that can affect returns and risk compared with buying the underlying foreign shares directly.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

What is the size of Novo Nordisk (NVO)'s current share repurchase programme?

Novo Nordisk expects to repurchase B shares for an amount of up to DKK 15 billion during a 12‑month period beginning 4 February 2026. Within this, a sub‑programme started 6 May 2026 allows repurchases of up to DKK 11,200,000,010.45 through 1 February 2027.

How many Novo Nordisk (NVO) shares have been repurchased under the 6 May 2026 programme?

Under the programme initiated on 6 May 2026, Novo Nordisk has accumulated repurchases of 15,170,000 B shares with a total transaction value of DKK 4,590,476,842 as of the latest reported transactions through 21 August 2026.

What are Novo Nordisk (NVO)'s total share repurchases since 4 February 2026?

Since 4 February 2026, Novo Nordisk has repurchased a total of 29,929,179 B shares at an average price of DKK 280.34 per B share, corresponding to an aggregate transaction value of DKK 8,390,476,831 as of 21 August 2026.

What percentage of Novo Nordisk (NVO)'s share capital is held as treasury shares?

Novo Nordisk holds 43,969,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the total share capital. The total number of A and B shares in the company, including treasury shares, is 4,465,000,000.

On which exchanges are Novo Nordisk (NVO) securities listed?

Novo Nordisk's B shares are listed on Nasdaq Copenhagen under the symbol Novo‑B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the symbol NVO.

What were the recent daily repurchases for Novo Nordisk (NVO) in August 2026?

From 17–21 August 2026, Novo Nordisk repurchased 205,000, 210,000, 210,000, 210,000, and 210,000 B shares respectively, at average prices between DKK 292.60 and DKK 299.08, for daily transaction values ranging from about DKK 59.99 million to DKK 62.81 million.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/24/2026 - 10:50 AM Accepted by SEC EDGAR 08/24/2026 - 10:49 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

August 24, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 24 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 17 August, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	14,125,000		4,281,660,830
17 August 2026	205,000	292.63	59,989,440
18 August 2026	210,000	292.60	61,446,140
19 August 2026	210,000	296.16	62,193,344
20 August 2026	210,000	299.08	62,807,428
21 August 2026	210,000	297.05	62,379,660
Accumulated under the programme	15,170,000		4,590,476,842

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 43,969,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 21 August 2026, Novo Nordisk has since 4 February 2026 repurchased a total 29,929,179 B shares at an average share price of DKK 280.34 per B share equal to a transaction value of DKK 8,390,476,831.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown	Liz Skrbkova (US)
+45 3079 9289	+1 609 917 0632
globalmedia@novonordisk.com	USMediaRelations@novonordisk.com
Investors:
Michael Novod	Sina Meyer
+45 3075 6050	+45 3079 6656
nvno@novonordisk.com	azey@novonordisk.com
Alex Bruce	Ida Schaap Melvold
+45 3444 2613	+45 3077 5649
axeu@novonordisk.com	idmg@novonordisk.com
Christoffer Togo Solgaard-Tullin	Mads Berner Bruun
+45 3079 1471	+45 3075 2936
cftu@novonordisk.com	mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 52 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: August 24, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer